Jan 11, 2018
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)
Jan 08, 2018
MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Dec 21, 2017
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Nov 22, 2017
MEI Pharma to Host Annual Meeting of Stockholders
Nov 08, 2017
MEI Pharma Reports First Quarter Fiscal Year 2018 Results
Nov 07, 2017
MEI Pharma to Present at Stifel 2017 Healthcare Conference
Sep 19, 2017
MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference
Sep 05, 2017
MEI Pharma Reports Fiscal Year 2017 Results
Sep 05, 2017
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
Aug 31, 2017
MEI Pharma to Present at Two Upcoming Investor Conferences
Aug 29, 2017
MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017
Aug 02, 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Jun 05, 2017
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
May 31, 2017
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma